Matthew Rutman, MD
Urology · New York, NYNPI 1083650170
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (52.0%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 23 manufacturers reported payments, led by Boston Scientific at 51.9% of the total. Reporting peaked in 2019 at $39,950 and has fallen 99.8% since, to $61 in 2025. Among urology clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 168 payments — averaging $562.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$49K
- Laborie Medical Technologies Corp.$36K
- Ferring Pharmaceuticals Inc.$5K
- Procept Biorobotics Corporation$1K
- Astellas Pharma US Inc$502
- Endo Pharmaceuticals Inc.$500
- plus $3K from 17 others
Across 12 payments — averaging $7395.62 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Urovant Sciences Inc$59K
- Sumitomo Pharma America, Inc.$29K
What the payments were for
- Consulting fees$36,44339%
- Speaking & faculty fees$49,15252%
- Travel & lodging$3,9954%
- Food & beverage$4,8475%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 42 | $49,026 |
| Laborie Medical Technologies Corp. | 13 | $35,550 |
| Ferring Pharmaceuticals Inc. | 5 | $4,937 |
| Procept Biorobotics Corporation | 11 | $1,305 |
| Astellas Pharma US Inc | 20 | $502 |
| Endo Pharmaceuticals Inc. | 1 | $500 |
| C. R. Bard, Inc. & Subsidiaries | 2 | $499 |
| AbbVie(2 entities) | 18 | $443 |
| Sumitomo Pharma America, Inc. | 13 | $346 |
| Medtronic(2 entities) | 6 | $339 |
| Axonics, Inc. | 4 | $175 |
| Neotract Inc. | 3 | $151 |
| Coloplast | 7 | $122 |
| Hollister Incorporated | 5 | $112 |
| Dentsply IH Inc. | 6 | $92 |
| Johnson & Johnson | 1 | $84 |
| Urovant Sciences Inc | 4 | $81 |
| Urogen Pharma, Inc. | 1 | $47 |
| Antares Pharma, Inc. | 2 | $40 |
| Ambu Inc. | 1 | $37 |
| Tolmar Pharmaceuticals, Inc. | 1 | $20 |
| 180 Medical, Inc. | 1 | $17 |
| Pfizer | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GENERAL BPH$24,016
- GREENLIGHT$15,604
- GENERAL - THERAPIES$5,209
- NOCDURNA$4,934
- REZUM$3,290
- AquaBeam Robotic System$923
- GreenLight XPS$750
- AQUABEAM SYSTEM$184
- INTERSTIM$141
- DALVANCE$123
- Bulkamid$103
How this compares
$94,438 in reported general payments places this provider in the 95th percentile of 952 urology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 670 | $477,643 |
| MyrbetriqMirabegron | 547 | $400,711 |
| Tamsulosin Hcl | 1,617 | $31,565 |
| Silodosin | 358 | $31,186 |
| Mirabegron ErMirabegron | 20 | $15,335 |
| AvodartDutasteride | 11 | $11,899 |
| Tadalafil | 70 | $10,856 |
| Finasteride | 632 | $10,181 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 367 | $8,970 |
| Dutasteride | 205 | $7,644 |
| Estradiol | 104 | $6,871 |
| Methenamine Hippurate | 62 | $5,403 |
| Trospium Chloride | 57 | $4,137 |
| Trospium Chloride ErTrospium Chloride | 16 | $2,834 |
| Potassium Citrate ErPotassium Citrate | 20 | $2,808 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa | $346 | $477,643670 claims |
| Astellas Pharma US IncMyrbetriq | $502 | $400,711547 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 952 urology providers in New York.
Other urology in New York
- Bilal ChughtaiNew York$658K
- Katie MurrayNew York$575K
- Neil BanderNew York$544K
- Robert ValenzuelaNew York$494K
- Kyrollis AttallaNew York$381K
- Benjamin BruckerNew York$364K
- Ketan BadaniNew York$285K
- Michael GrassoNew York$284K
- Mantu GuptaNew York$229K
- Robin SmithNew York$215K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.